Organigram Holdings Inc (OGI) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Organigram Product Development Collaboration Completes Landmark Clinical Study on Nanoemulsion Technology

FAST™ Nanoemulsion Technology Expected to be a Competitive Advantage for Organigram’s Ingestible Portfolio Organigram Holdings Inc. (NASDAQ: OGI...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Organigram to Report Third Quarter Fiscal 2024 Results on August 13, 2024

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Organigram Announces Appointment of Craig Harris to Board of Directors

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Organigram to Bolster Auto-Flower and Rare Cannabinoid Portfolio with Partial Third Tranche Investment of US $1M into Phylos

The partial third tranche investment is expected to enable Organigram to expand its product portfolio, addressing consumer demand for unique and...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Organigram investit dans Sanity Group, un chef de file du cannabis en Allemagne

Ce second investissement du fonds Jupiter renforce l’accès européen d’Organigram, y compris au marché à forte...

Organigram Invests in Sanity Group, a Leading German Cannabis Company

Second “Jupiter” investment strengthens Organigram’s European access, including to the high-growth market of...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Organigram Signs Three Year Supply Agreement with Avida Medical in UK

Over a three-year period, Organigram expects to supply 1,700 kilograms of high-quality medical cannabis...